Drugs / AP 10-701
AP 10-701
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03910972 | Oct 2019 → Nov 2024 | Schistosoma mansoni infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP 10-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03910972 ↗ |
| Known as | GLA-AF | “AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist.” NCT03910972 ↗ |
| Known as | Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF) | “AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist.” NCT03910972 ↗ |
| Action | Activate | “AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist.” NCT03910972 ↗ |
| Route | Intramuscular | “Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose” NCT03910972 ↗ |